Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06467344 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
A Phase 1 study of Stargardt Disease and Cone-Rod Dystrophy, sponsored by Ascidian Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 10
- Study locations
NCT06467344 is a Phase 1 study of Stargardt Disease and Cone-Rod Dystrophy that is actively recruiting participants, run by Ascidian Therapeutics. The registered enrollment target is 15 participants, below the 90-participant average among 16 other Stargardt Disease trials with a reported enrollment target (83% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT06467344, a Phase 1 study of Stargardt Disease and Cone-Rod Dystrophy, is actively recruiting participants, sponsored by Ascidian Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Conditions Studied
Interventions
- DRUG ACDN-01
Study Locations (10)
Florida
- Vitreo Retinal Associates - Gainesville
- Bascom Palmer Eye Institute - Miami
Texas
- Retina Foundation of the Southwest - Dallas
- Retina Consultants of Texas - Houston
California
- University of San Francisco - San Francisco
Maryland
- Wilmer Eye Institute at John Hopkins - Baltimore
Massachusetts
- Massachusetts Eye and Ear - Boston
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Ohio
- Cincinnati Eye Institute - Cincinnati
Oregon
- Casey Eye Institute OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06467344
The ClinicalTrials.gov registry entry for NCT06467344 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 16 other Stargardt Disease trials with a reported enrollment target (83% lower). The listed sponsor is Ascidian Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which ACDN-01 is the first listed.
NCT06467344 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06467344 about?
NCT06467344 is a clinical study titled "Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)". This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
What is the current status of trial NCT06467344?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-06-11. Estimated completion is 2030-12-01.
What conditions does trial NCT06467344 study?
This clinical trial studies the following conditions: Stargardt Disease, Cone-Rod Dystrophy, Stargardt Disease 1, Juvenile Macular Degeneration.
What interventions are being tested in trial NCT06467344?
The interventions under investigation include: ACDN-01 (DRUG).
Who is sponsoring clinical trial NCT06467344?
This trial is sponsored by Ascidian Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06467344 being conducted?
This trial has 10 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
Oral Metformin for Treatment of ABCA4 Retinopathy
RECRUITING · Phase 1
-
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.